Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN1A | P35498 | 2/20 | 0.44 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.44 |
| ▸ | SCN8A | Q9UQD0 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.40 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.39 |
| ▸ | AURKA | O14965 | 1/20 | 0.39 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.39 |
| ▸ | GPR88 | Q9GZN0 | 1/20 | 0.38 |
| ▸ | MAP3K8 | P41279 | 1/20 | 0.37 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.37 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.37 |
| ▸ | HSD17B13 | Q7Z5P4 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3518138 | 0.90 | RPS6KB1 (0.46) | SCN1ASCN5ASCN8ARPS6KB1AURKA | |
| SCHEMBL3514710 | 0.80 | P2RX7 (0.44) | MAPK1POLB | |
| SCHEMBL3514910 | 0.77 | KDM4E (0.43) | MEN1KMT2A | |
| SCHEMBL3516717 | 0.77 | KDM4E (0.43) | MEN1KMT2A | |
| SCHEMBL3514723 | 0.77 | KDM4E (0.43) | MEN1KMT2A | |
| SCHEMBL3515736 | 0.75 | ACP1 (0.47) | POLB | |
| SCHEMBL3515097 | 0.74 | SMN1; SMN2 (0.48) | SCN5APOLBKMT2A | |
| SCHEMBL3516034 | 0.74 | AURKA (0.43) | RPS6KB1AURKAPOLB | |
| SCHEMBL3518140 | 0.70 | FEN1 (0.44) | AURKAPOLBMEN1KMT2A | |
| SCHEMBL3516223 | 0.69 | BACE1 (0.49) | RPS6KB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100056516-A1 | 1-HYDROXY NAPHTHYRIDINE COMPOUNDS AS ANTI-HIV AGENTS | MERCK SHARP & DOHME CORP. | 2010-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056516-A1 | 1-HYDROXY NAPHTHYRIDINE COMPOUNDS AS ANTI-HIV AGENTS | RNASEH1, RNASE1, RNASEL | SCN1A 1555/4885SCN5A 2983/4885SCN8A 3072/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.